An important recent research project concerns the synthesis and practical development of novel platinum complexes as possible antitumor agents.

Ruthenium, unlike traditional platinum complexes, shows greater resistance to hydrolysis and more selective action on tumors.

Structural control is easier than for ruthenium complexes due to the square planar structure of the platinum complex.

The bright yellow compound is widely used as a precursor to other platinum complexes.

Compared with platinum complexes, those of ruthenium show greater resistance to hydrolysis and more selective action on tumors.

This mixture consists of a short hydrosilane crosslinker that contains a catalyst made from a platinum complex.

Along with cisplatin, many other platinum complexes are potential therapeutics.

As seen by these few examples, platinum complexes are a particularly active area of research for metal-based medicines.

The platinum complex has been used in many syntheses:

Ruthenium complex and platinum complexes of bipy exhibit intense luminescence, which may have practical applications.